� DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company, announced that one of its academic development partners has initiated a second human clinical trial of RiVax� in healthy volunteers. RiVax� is a recombinant subunit vaccinum designed to induce security against vulnerability to ricin toxin, a category B biothreat. This new trial is intended to judge the base hit and immunogenicity of an improved expression of the vaccine containing an ancillary that is expected to result in long durable and high levels of protective antibodies. The new trial is being conducted as erated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, Inc., please visit the Company's internet site located at http://www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec� for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec�. Where possible, DOR has tried to identify these forward-looking statements by victimisation words such as "anticipates," "believes," "intends," or standardised expressions. These statements ar subject to a
